πŸ‡ΊπŸ‡Έ FDA
Patent

US 7084239

Cancer peptides of NY-ESO-1/CAG-3

granted A61KA61K38/00

Quick answer

US patent 7084239 (Cancer peptides of NY-ESO-1/CAG-3) held by The United States of America, as represented by the Department of Health and Human Services expires Mon Jul 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Department of Health and Human Services
Grant date
Tue Aug 01 2006 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 27 2026 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
41
CPC classes
A61K, A61K38/00